Compare ZJYL & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZJYL | GBIO |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 36.3M |
| IPO Year | 2023 | 2020 |
| Metric | ZJYL | GBIO |
|---|---|---|
| Price | $0.16 | $5.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.88 |
| AVG Volume (30 Days) | ★ 1.3M | 93.6K |
| Earning Date | 08-20-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $22,826,624.00 | $15,270,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.19 | ★ N/A |
| Revenue Growth | ★ 13.42 | N/A |
| 52 Week Low | $0.11 | $3.00 |
| 52 Week High | $1.03 | $9.25 |
| Indicator | ZJYL | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 52.25 |
| Support Level | $0.12 | $5.41 |
| Resistance Level | $0.18 | $5.72 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 30.12 | 66.67 |
Jin Medical International Ltd offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other living aids products to be used by people with disabilities or impaired mobility. The company's products are sold to distributors in both China and overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, and nursing products. Geographically, it generates the majority of its revenue from Japan.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.